Evidence map›Paper›PMID 42369857›Full record

ArticleWellcome open research2026

Viral hepatitis and liver disease in the Mongolian community in London ('MoLo'): A mixed methods study protocol to investigate the epidemiology and burden of disease to inform clinical and public health interventions.

Emily Martyn, Nara Dashdorj, Jessica Carter, Indrajit Ghosh, Enkh-Oyun Amarbayasgalan, Khadija Said Mohammed, Elizabeth Waddilove, Marion Delphin, Kathryn Jack, Camila Picchio and 13 more

Abstract read
In one paragraph

Article in Wellcome open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Emily MartynThe Francis Crick Institute, London, England, UK.ORCID https://orcid.org/0000-0003-4981-9298
Nara DashdorjOnom Foundation, Ulaanbaatar, Ulaanbaatar, Mongolia.
Jessica CarterMigrant Health Research Group, Institute for Infection and Immunity, City St George's University of London, London, UK.
Indrajit GhoshHepatitis Service, Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, England, UK.ORCID https://orcid.org/0009-0009-5311-9885
Enkh-Oyun AmarbayasgalanMongolian Community Organisation, London, UK.
Khadija Said MohammedThe Francis Crick Institute, London, England, UK.ORCID https://orcid.org/0000-0001-7467-7290
Elizabeth WaddiloveThe Francis Crick Institute, London, England, UK.
Marion DelphinThe Francis Crick Institute, London, England, UK.
Kathryn JackHepatology Department, Nottingham University Hospitals NHS Trust, Nottingham, England, UK.ORCID https://orcid.org/0000-0002-8596-4073
Camila PicchioUniversity of Barcelona, Barcelona Institute for Global Health, Barcelona, Spain.
Joy KoHepatitis Service, Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, England, UK.
Michelle BerkeleyDivision of Infection and Immunity, University College London Faculty of Medical Sciences, London, England, UK.
Rubin Rose-KeyDivision of Infection and Immunity, University College London Faculty of Medical Sciences, London, England, UK.ORCID https://orcid.org/0009-0003-2597-5226
Eleni NastouliDepartment of Infection, Immunity and Inflammation, University College London, Great Ormond Street Institute of Child Health, London, England, UK.
Sema MandalBlood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK.
Monica DesaiBlood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK.
Sally HargreavesMigrant Health Research Group, Institute for Infection and Immunity, City St George's University of London, London, UK.
Douglas GrayThe Francis Crick Institute, London, England, UK.
Jennifer HayThe Francis Crick Institute, London, England, UK.
James MacRaeThe Francis Crick Institute, London, England, UK.ORCID https://orcid.org/0000-0002-1464-8583
Stuart FlanaganHepatitis Service, Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, England, UK.
Julian SureyDivision of Infection, University College London Hospitals NHS Foundation Trust, London, England, UK.ORCID https://orcid.org/0000-0003-2411-0477
Philippa C MatthewsThe Francis Crick Institute, London, England, UK.ORCID https://orcid.org/0000-0002-4036-4269

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic viral hepatitis infections (hepatitis B (HBV), C (HCV) and D viruses (HDV)) are responsible for over 1 million deaths annually, due to cirrhosis and liver cancer. Mongolia has a high prevalence of all these infections, resulting in the highest incidence and mortality from liver cancer in the world. Other factors, such as metabolic dysfunction-associated steatotic liver disease (MASLD) can impact viral hepatitis, although the interaction is not fully understood. Several successful viral hepatitis screening programmes have been carried out among Mongolians living in Spain, USA, and Sweden. Protocol: We describe a community-informed protocol for the implementation of liver health screening among Mongolians living in London (UK), designed by a multi-disciplinary team. This observational, mixed-methods study ('Hep-MoLo') has three domains. (i) In the clinical domain, liver screening events will be held in London, in collaboration with the Mongolian Community Organisation. An awareness-raising educational component will precede point-of-care screening for blood-borne infections (HBV, HCV, HIV), liver fibrosis and steatosis, and screening for cardiometabolic risk factors (obesity, hypertension, dyslipidaemia, diabetes); (ii) Laboratory studies will focus on the interaction between HBV and MASLD; (iii) A qualitative approach will be used to explore community views on liver health screening, access and engaging in care. Discussion: This protocol provides a framework for a public health intervention targeting a high-risk population, combined with laboratory and qualitative research to give a multi-dimensional insight into viral hepatitis and liver health in the London Mongolian community. This is a community-academic-clinical partnership, fostering collaboration to generate data to inform clinical and public health interventions.

Indexed as

blood borne virusCommunity engagementepidemiologyHBVHCVHDVHIVimplementation researchInclusion Healthliver healthMASLDmixed-methodsMongoliaqualitativescreening

Identifiers

PMID42369857
PMCPMC13305554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.